FDA-cleared profile

CogNet AI-MT+

Medcognetics, Inc.

Prioritizes suspicious screening DBT examinations for MQSA interpreting physicians; every examination remains subject to full physician review.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
Prioritizes suspicious screening DBT examinations for MQSA interpreting physicians; every examination remains subject to full physician review.
FDA source Exact FDA submission Checked 2026-09-05
Intended users
MQSA qualified interpreting physicians
Public source Exact FDA submission Checked 2026-09-01

Intended-user text reported in the exact-submission ACR model card.

Care setting and population
Adult
Public source Exact FDA submission Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Workflow role
Triage or notification support
Public source Exact FDA submission Checked 2026-08-31

Conservative normalization of explicit wording in an exact-submission source.

Required input
Four bilateral DICOM For Presentation DBT views from Hologic Selenia Dimensions; validation excluded breast implants and post-surgical studies.
FDA source Exact FDA submission Checked 2026-09-05
Output and human action
DICOM Secondary Capture and private DICOM tags with Suspicious/red-diamond or Processed/blue-circle status; no diagnostic viewer is supplied.
FDA source Exact FDA submission Checked 2026-09-05
Limitations
Passive triage only, not diagnostic information; output cannot remove images or replace MQSA physician review and is limited to validated Hologic Dimensions DBT input.
FDA source Exact FDA submission Checked 2026-09-05

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K252482
FDA source Exact FDA submission Checked 2026-08-31
Modality
Mammography/DBT
FDA source Exact FDA submission Checked 2026-09-05
Anatomy
Breast
FDA source Exact FDA submission Checked 2026-09-05
Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2025-12-11
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
Input may be routed from PACS, modality or a DICOM router; output may populate an API worklist column.
FDA source Exact FDA submission Checked 2026-09-05
Deployment and data flow
Cloud-based licensed access is described in the summary.
FDA source Exact FDA submission Checked 2026-09-05
Security and privacy
Vendor documentation pending
Vendor confirmation Exact product version Checked 2026-09-05

Technical controls in the summary do not establish a current formal security attestation.

Training and support
Licensed users receive a user manual and quality/technical staff provide initial usage support.
FDA source Exact FDA submission Checked 2026-09-05
Monitoring and change control
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-08-13

Local acceptance testing, production monitoring, drift review, update control, and incident escalation require a current vendor and site-specific governance plan.

Current family scope note

The vendor's embedded AI material is labeled investigational and is not treated as a cleared deployment capability for CogNet AI-MT+.

product family · checked 2026-09-05

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
The FDA summary reports a standalone retrospective diagnostic-enriched DBT study; no general-population screening performance claim is made.
FDA source Exact FDA submission Checked 2026-09-05
Reported sensitivity
88.09
FDA source Exact FDA submission Checked 2026-09-05

Standalone retrospective endpoint; study context applies.

Reported specificity
91.56
FDA source Exact FDA submission Checked 2026-09-05

Standalone retrospective endpoint; study context applies.

Sensitivity

0.8809 proportion

Standalone suspicious-exam triage classification in 806 women; 403 biopsy-proven malignancy and 403 benign/negative reference cases.

Tested version: CogNet AI-MT+

Specificity

0.9156 proportion

Standalone suspicious-exam triage classification in 806 women; 403 biopsy-proven malignancy and 403 benign/negative reference cases.

Tested version: CogNet AI-MT+

CogNet AI-MT+ regulatory standalone DBT evaluation

Retrospective standalone diagnostic-enriched evaluation. · 806 women using Hologic Selenia Dimensions DBT; 50% cancer-enriched.

exact submission · Tested version: CogNet AI-MT+ · n=806 · Independence not established

K252482

Not representative of screening prevalence.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Not established in reviewed sources
Reviewed sources checked Exact product version Checked 2026-09-06
Reimbursement and coding
Research pending
Needs research Exact FDA submission Checked 2026-09-06

No applicable payer policy reviewed.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-06Last searched
25Fields reviewed
9Source classes checked
0Reviewed PubMed leads
0Reviewed trial leads
0Unreviewed FDA recall leads

No stored literature or trial candidates; empty metadata snapshots were screened. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, literature index, trial registry, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-05.

Alternatives

Related tools to compare

FDA-cleared K252954

MammoSightAI

Neurocareai, Inc. (Dba Savelife.Ai)

Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-05-04
FDA-cleared K233108

VinDr-Mammo

VinBigData Joint Stock Company

FDA product code QFM identifies this device class as Radiological Computer-Assisted Prioritization Software For Lesions. Radiological computer-assisted prioritization software for...

Modality
Mammography/DBT
Anatomy
Breast
Decision
2024-05-23
FDA-cleared K200905

HealthMammo

Zebra Medical Vision Ltd.

FDA product code QFM identifies this device class as Radiological Computer-Assisted Prioritization Software For Lesions. Radiological computer-assisted prioritization software for...

Modality
Mammography/DBT
Anatomy
Breast
Decision
2020-07-16
FDA-cleared K260714

MammoScreen® (5)

Therapixel

Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-26